Molecular markers of Plasmodium falciparum drug resistance;Marqueurs moléculaires des résistances de Plasmodium falciparum aux antipaludiques

Medecine Tropicale

Volumn 69, Issue 6, 2009, Pages 606-612

  Eboumbou Moukoko, E C ^a,b,c   Bogreau, H ^b   Briolant, S ^b   Pradines, B ^b   Rogier, C ^b  

^a UNIVERSITY OF DOUALA   (Cameroon)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c UNIVERSITY OF BUEA   (Cameroon)

Author keywords

Anti malarial drugs; Malaria; Markers; Plasmodium falciparum; Resistance

Indexed keywords

AMODIAQUINE; ATOVAQUONE; CHLOROQUINE; CYCLOGUANIL; MEFLOQUINE; MOLECULAR MARKER; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT;

ANTIMALARIAL DRUG RESISTANCE; DRUG EFFICACY; DRUG MONITORING; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; MALARIA CONTROL; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PARASITE EXAMINATION; PLASMODIUM FALCIPARUM; PREDICTION; PROTOZOAL GENETICS; REVIEW; GENETIC MARKER; GENETICS; GENOTYPE; HUMAN; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE;

ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENETIC MARKERS; GENOTYPE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 77649217640     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. WHO. The world malaria report 2008. Geneva : World Health Organization; 2008. Report No. : WHO/HTM/GMP/2008.1.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434 : 214-7. (Pubitemid 40388051)
3. WHO. Susceptibility of Plasmodium falciparum to antimalarial drugs : report on global monitoring : 1996-2004. World Health Organisation ed, Geneva, 2005. Report No. : WHO/HTM/MAL/2005.1103.
4. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, et al. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 1998; 321 : 689-97. (Pubitemid 28438430)
5. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001; 64 : 12-7.
6. Ogbonna A, Uneke CJ. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. Trans R Soc Trop Med Hyg 2008; 102 : 621-7.
7. Nyarango PM, Gebremeskel T, Mebrahtu G, Mufunda J, Abdulmumini U, Ogbamariam A, et al.A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 2006; 5 : 33.
8. Dondorp A, Nosten F, Yi P, Das DB, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum Malaria. N Engl J Med 2009; 361 : 455-67.
9. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin- resistant malaria in western Cambodia. N Engl J Med 2008; 359 : 2619-20.
10. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008; 14: 716-9. (Pubitemid 351838633)
11. WHO. Resistance of malaria parasites to drugs. World Health Organization, Geneva, 1965.
12. WHO. Chemotherapy of malaria and resistance to antimalarials: Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1973; 529 : 1-121.
13. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009; 8 : 89.
14. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, et al. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol 2003; 49 : 977-89. (Pubitemid 36981343)
15. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drugresistance. Acta Trop 2005; 94 : 181-90. (Pubitemid 40720325)
16. Marfurt J, Müller I, Sie A, Oa O, Reeder JC, Smith TA, et al. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malar J 2008; 7 : 61.
17. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007; 51 : 991-7. (Pubitemid 46355285)
18. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether- lumefantrine (Coartem). J Infect Dis 2005; 191 : 1014-7. (Pubitemid 40349821)
19. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403 : 906-9. (Pubitemid 30130994)
20. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364 : 438-47. (Pubitemid 39036891)
21. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009; 8 : 11.
22. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum : what next? Trends Parasitol 2001; 17 : 582-8. (Pubitemid 34088118)
23. Hyde JE. Exploring the folate pathway in Plasmodium falciparum. Acta Trop 2005; 94 : 191-206. (Pubitemid 40720326)
24. Ekala MT, Khim N, Legrand E, Randrianarivelojosia M, Jambou R, Fandeur T, et al. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar J 2007; 6 : 164.
25. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J. Apparent absence of atovaquone/ proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 2006; 57 : 110-5. (Pubitemid 43057066)
26. Savini H, Bogreau H, Bertaux L, Bouchiba H, Kraemer P, Parzy D, et al. First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparumduring treatment in a traveler in Comoros. Antimicrob Agents Chemother 2008; 52 : 2283-4. (Pubitemid 351758581)
27. Bennett TN, Patel J, Ferdig MT, Roepe PD. Plasmodium falciparumNa+/H+ exchanger activity and quinine resistance. Mol Biochem Parasitol 2007; 153 : 48-58. (Pubitemid 46517676)
28. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004; 52 : 985-97. (Pubitemid 38916169)
29. Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, et al. Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother 2009; 53 : 1926-30.
30. Raj DK, Mu J, Jiang H, Kabat J, Singh S, Sullivan M, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem 2009; 284 : 7687-96.
31. Klokouzas A, Tiffert T, van Schalkwyk D, Wu CP, van Veen HW, Barrand MA, et al. Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochem Biophys Res Commun 2004; 321 : 197-201. (Pubitemid 39055624)
32. Henry M, Briolant S, Fontaine A, Mosnier J, Baret E, Amalvict R, et al. in vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2008; 52 : 2755-9.
33. Ursing J, Zakeri S, Gil JP, Björkman A. Quinoline resistance associated polymorphisms in the pfcrt, pfmdr1 and pfmrp genes of Plasmodium falciparum in Iran. Acta Trop 2006; 97 : 352-6.
34. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, et al. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparummalaria. Antimicrob Agents Chemother 2009; 53 : 2248-52.
35. Dahlström S, Veiga MI, Mårtensson A, Björkman A, Gil JP. Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents Chemother 2009; 53 : 2553-6.
36. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005; 366 : 1960-3. (Pubitemid 41713986)
37. Briolant S, Almeras L, Fusai T, Rogier C, Pradines B. Cyclines et paludisme. Med Trop 2007; 67 : 86-96. (Pubitemid 350157239)
38. Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, et al.A Multinormal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemosusceptibility to doxycycline. Antimicrob Agents Chemother 2009; 53 : 688-95.
39. Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphism and copy numbers of pftetQ and pfmdt. J Infect Dis 2009; sous presse.
40. Briolant S, Fusai T, Rogier C, Pradines B. Tetracyclines antibiotics in Malaria. Open Trop Med J 2008; 1 : 31-46.
41. Djimdé AA, Dolo A, Ouattara A, Diakité S, Plowe CV, Doumbo OK. Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis 2004; 190 : 853-5. (Pubitemid 39050017)
42. Djimdé A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001; 358 : 890-1. (Pubitemid 32900575)
43. Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, et al.World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J 2007; 6 : 121.
44. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant malaria. N Engl J Med 2001; 344 : 257-63.
45. Sibley CH, Barnes KI, Watkins WM, Plowe CV. A network to monitor antimalarial drug resistance: a plan for moving forward. Trends Parasitol 2008; 24 : 43-8.